Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.
about
HPV related diseases in males: a heavy vaccine-preventable burdenInterventions to increase HPV vaccination coverage: A systematic reviewEarly direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic reviewPopulation-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysisEvaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort StudyModeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.Qualitative study of the feasibility of HPV vaccine delivery to young adolescent girls in Vietnam: evidence from a government-implemented demonstration program.Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.Trust versus concerns-how parents reason when they accept HPV vaccination for their young daughter.Attitudes toward HPV vaccination among low-income and minority parents of sons: a qualitative analysis.Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies.Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan AfricaSexually transmitted infections after bereavement - a population-based cohort studyQuadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.Impact of HPV vaccination on anogenital warts and respiratory papillomatosisImpact of HPV immunization on the detection of cervical disease.Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data.A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer.9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents.Oral human papillomavirus (HPV) prevalence in youth and cervical HPV prevalence in women attending a youth clinic in Sweden, a follow up-study 2013-2014 after gradual introduction of public HPV vaccination.The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada.Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program.Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark.Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty.Evidence for effectiveness of a national HPV vaccination programme: national prescription data from New Zealand.Incidence of anogenital warts in Liuzhou, south China: a comparison of data from a prospective study and from the national surveillance system.Monitoring the impact of HPV vaccine in males-Considerations and challenges.Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.HPV prophylactic vaccines: lessons learned from 10 years experience
P2860
Q27010120-B6FE48D0-FC1D-40B4-998E-44524FF5DC92Q27311022-B256B0B6-6830-4A27-AB0C-44754E8166A6Q28081927-F40BEEF0-E365-4B67-AA86-D9EC3E67B84DQ28084924-53590E45-94D6-4D9D-9475-32DD16286294Q28647510-638105DC-0128-4FDC-A4AE-DAAE98802433Q30573204-09ED9B7A-F6E9-49F8-A81E-4F8B557B7B13Q30682187-5E3FCDFD-119C-4F87-9DF8-345CB112920EQ33792465-A71D07E8-DD34-4881-8DDE-0BCBCDC2CC5CQ33848793-ABE1D879-26A3-4AA1-8E2D-084816D7C5B9Q34311160-C7142031-30E7-4850-A7BE-13D9BA81787AQ34567319-4C6CB127-DAEC-4E4C-95D5-1079FAE7181BQ35677956-24BA55EF-4E6E-4F47-A669-E9D9AA152D19Q35784964-661FE55A-2CE5-43E9-AF9D-4961B3343368Q35887646-F3BE84EF-02A4-4FAF-A1EE-990E35ECBED7Q36104638-82F739B4-C2F7-48D0-B150-C2BE4A8832A1Q36734952-8C861B93-0641-4969-8F94-B088DFF46228Q37284313-A3D5CFCA-2B3A-404B-B1AA-E5A0042153C9Q38194249-8240853C-ED5E-4DE8-9F74-AF140DB31F95Q38399052-B7A73524-7DA9-47FC-9425-DCA166810B47Q38418103-A2610D83-EFA2-4148-A1D5-90AD8836CF47Q38586257-FEBC56FA-0458-4A4E-82D8-F2E841C6F8D7Q40215017-9AC6B52F-CA84-4A19-AC8A-3E3C634F35B1Q41672842-9B598A7F-515A-4424-B201-253FFD2DDE21Q41923803-ACF102E2-E6F2-4727-962A-1B03FB81ED32Q42220415-F519563D-97F2-4A2C-AC3A-68DE20C10275Q42236236-42357EB1-2E15-416A-8B35-7E59C94B9A55Q42287949-38B7E61A-3C3C-4B7B-9B2D-91AED10A2845Q43893716-350252D1-D83E-4C14-B567-82052BCAC621Q45854761-60BA0732-2094-47B8-903A-5345F1ECD92DQ47280272-E2B61200-EF2E-4A71-99E8-92D6EFCB556AQ50091385-1264CA3C-03A2-46BC-9495-EE73FA9D495EQ51872328-029FD0DC-DFAB-4F20-BFFD-8B18E8F9BDBEQ56067928-63F436BF-6AE3-4211-9DC5-DADB9BF1926E
P2860
Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Incidence of genital warts in ...... omavirus vaccine availability.
@en
Incidence of genital warts in ...... omavirus vaccine availability.
@nl
type
label
Incidence of genital warts in ...... omavirus vaccine availability.
@en
Incidence of genital warts in ...... omavirus vaccine availability.
@nl
prefLabel
Incidence of genital warts in ...... omavirus vaccine availability.
@en
Incidence of genital warts in ...... omavirus vaccine availability.
@nl
P2093
P2860
P356
P1476
Incidence of genital warts in ...... lomavirus vaccine availability
@en
P2093
Emma Frans
Eva Herweijer
Hasse Walum
Pär Sparén
P2860
P304
P356
10.1093/INFDIS/JIS405
P407
P577
2012-07-18T00:00:00Z